In vitro profiling of endocrine disrupting potency of 2,2',4,4'-tetrabromodiphenyl ether (BDE47) and related hydroxylated analogs (HO-PBDEs).

The potential of 2,2',4,4'-tetrabromodiphenyl ether (BDE47) and its related hydroxylated analogs (2'-HO-BDE28, 6-HO-BDE47, 4'-HO-BDE17, and 4'-HO-BDE49) to modulate estrogen/thyroid/androgen receptor-(ER, TR, AR), mediated responses were investigated by use of reporter gene assays. Exposure to 1 or 10 μM, 4'-HO-BDE17 significantly up-regulated expression of Luc, whereas other four chemicals did not induce Luc expression under control of the ER. Anti-estrogenic potency was observed for 4'-HO-BDE17 (IC50=1.14 μM)>6-HO-BDE47 (IC50=2.65 μM)>2'-HO-BDE28 (IC50=9.49 μM)>BDE47 (IC50=21.11 μM). No anti-estrogenic effect of 4'-HO-BDE49 was observed. Both 4'-HO-BDE17, 4'-HO-BDE49 resulted in greater responses of Luc expression induced by T3. BDE47, 2'-HO-BDE28, 6-HO-BDE47 did not show any effect on the expression of Luc induced by 5 nM T3. 6-HO-BDE47 (IC50=0.34 μM)>4'-HO-BDE17 (IC50=1.41 μM)>BDE47 (IC50=3.83 μM)>2'-HO-BDE28 (IC50=29.22 μM) exhibited anti-androgenic potency, while 4'-HO-BDE49 did not show androgenic transcriptional activity.